文献速递湿疹皮炎与荨麻疹

靶向2型信号生物制剂治疗特应性皮炎的结构与热力学机制比较综述

Biologic Therapies Targeting Type 2 Signaling in Atopic Dermatitis: A Comparative Review of Structural and Thermodynamic Differences in Mechanism of Action.
PubMed 文献 · J Invest Dermatol · 2025-08-06

本综述从分子视角分析IL-4/IL-13信号的结构与热力学特性,比较dupilumab、tralokinumab、lebrikizumab和rademikibart的作用机制差异。核心结论是每种生物制剂通过在不同能量步骤干扰细胞因子-受体信号复合物组装而发挥独特功能,可解释患者反应差异。

要点

  • IL-4和IL-13是特应性皮炎2型免疫的关键细胞因子。
  • 四种生物制剂阻断IL-4/IL-13信号的分子机制和能量步骤不同。
  • 机制差异可能解释患者对不同生物制剂的个体化反应。

核心结论

  • 每种用于特应性皮炎临床的生物制剂通过在不同能量步骤破坏细胞因子-受体信号复合物组装而发挥独特作用。

研究设计与样本

  • 本文为叙述性综述,分析IL-4/IL-13信号的结构与热力学特性及其对生物制剂作用机制差异的影响。

主要发现

  • 特应性皮炎中2型免疫涉及IL-4和IL-13升高,IL-31、IL-22、IFN-γ和胸腺基质淋巴细胞生成素也参与急慢性状态。
  • 靶向IL-4/IL-13通路的生物制剂总体疗效良好,但不同生物制剂间观察到患者个体反应差异。
  • dupilumab、tralokinumab、lebrikizumab和rademikibart通过不同机制破坏细胞因子-受体信号复合物组装。

临床怎么用

  • 临床选择生物制剂时可考虑不同作用机制的能量步骤差异对个体反应的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Atopic dermatitis (AD) is a chronic skin disease characterized by heterogeneous clinical morphology, immune dysregulation, and disease burden. A key component of the immune dysregulation in AD occurs through type 2 immunity, with elevations in IL-4 and IL-13. Multiple other cytokines contribute to both acute and chronic states of AD, including IL-31, IL-22, IFN-γ, and thymic stromal lymphopoietin. Several biologic therapies targeting type 2 cytokine (IL-4 and IL-13) signaling through distinct mechanisms of action (MOAs) have been developed, with more expected in the future, including with multivalency. Although biologics targeting the IL-4/IL-13 pathway have good overall efficacy for AD, variable individual patient responses to different biologics have been observed. This review analyzes and addresses the function of biologic therapies for AD from a fresh molecular perspective. It describes the structural and thermodynamic properties of IL-4/IL-13 signaling and how these properties inform MOA differences between the AD biologics dupilumab, tralokinumab, lebrikizumab, and rademikibart and translates the molecular science into potential clinical implications of these MOA differences. The fundamental conclusion is that each of the biologics currently in clinical use for treating AD function very uniquely by disrupting the assembly of the cytokine-receptor signaling complex at different energetic steps.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Bunick CG. Biologic Therapies Targeting Type 2 Signaling in Atopic Dermatitis: A Comparative Review of Structural and Thermodynamic Differences in Mechanism of Action. J Invest Dermatol. 2025. PMID: 40767793. doi:10.1016/j.jid.2025.06.1574

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。